miR-656 inhibits glioma tumorigenesis through repression of BMPR1A

Carcinogenesis

Volumn 35, Issue 8, 2014, Pages 1698-1706

  Guo, Mian ^a,b,c   Jiang, Zhenfeng ^b   Zhang, Xiaoming ^a   Lu, Dunyue ^b,d   Ha, Albert Duy ^c   Sun, Jiahang ^a   Du, Wenzhong ^a   Wu, Zhichao ^a   Hu, Li ^b   Khadarian, Kevork ^c   Shen, Jia ^c   Lin, Zhiguo ^b  

^a THE SECOND AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BONE MORPHOGENETIC PROTEIN 2; BONE MORPHOGENETIC PROTEIN RECEPTOR 1A; CYCLIN B; CYCLIN D1; GELATINASE B; MICRORNA; MICRORNA 656; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN P21; PROTEIN P27; RECOMBINANT BONE MORPHOGENETIC PROTEIN 2; SMAD PROTEIN; UNCLASSIFIED DRUG; BMPR1A PROTEIN, HUMAN; BONE MORPHOGENETIC PROTEIN RECEPTOR 1; MESSENGER RNA; SMALL INTERFERING RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER GROWTH; CANCER SIZE; CARCINOGENESIS; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; DOWN REGULATION; GENE REPRESSION; GLIOMA; GLIOMA CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BRAIN; BRAIN TUMOR; CANCER GRADING; CASE CONTROL STUDY; CELL CYCLE; CELL MOTION; CELL TRANSFORMATION; COMPARATIVE STUDY; DRUG SCREENING; ENZYME IMMUNOASSAY; GENETICS; METABOLISM; NUDE MOUSE; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; TUMOR INVASION; WESTERN BLOTTING; WOUND HEALING;

ANIMALS; BLOTTING, WESTERN; BONE MORPHOGENETIC PROTEIN RECEPTORS, TYPE I; BRAIN; BRAIN NEOPLASMS; CASE-CONTROL STUDIES; CELL CYCLE; CELL MOVEMENT; CELL PROLIFERATION; CELL TRANSFORMATION, NEOPLASTIC; GLIOMA; HUMANS; IMMUNOENZYME TECHNIQUES; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICRORNAS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TUMOR CELLS, CULTURED; WOUND HEALING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84905700344     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgu030     Document Type: Article

References (46)

1. Dolecek,T.A.et al. (2012) CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro. Oncol., 14 (suppl. 5), v1-49.
2. Kleihues,P.et al. (2002) The WHO classification of tumors of the nervous system. J. Neuropathol. Exp. Neurol., 61, 215-25; discussion 226.
3. Stupp,R. et al. European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med., 352, 987-996.
4. Leighton,C.et al. (1997) Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J. Clin. Oncol., 15, 1294-1301.
5. Wozney,J.M.et al. (1988) Novel regulators of bone formation: molecular clones and activities. Science, 242, 1528-1534.
6. Zhao,G.Q. (2003) Consequences of knocking out BMP signaling in the mouse. Genesis, 35, 43-56.
7. Carragee,E.J.et al. (2011) A critical review of recombinant human bone morphogenetic protein-2 trials in spinal surgery: emerging safety concerns and lessons learned. Spine J., 11, 471-491.
8. Miyazono,K.et al. (2005) BMP receptor signaling: transcriptional targets, regulation of signals, and signaling cross-talk. Cytokine Growth Factor Rev., 16, 251-263.
9. Lawrence,M.C.et al. (2008) The roles of MAPKs in disease. Cell Res., 18, 436-442.
10. Liu,C.et al. (2009) Expression pattern and clinical prognostic relevance of bone morphogenetic protein-2 in human gliomas. Jpn. J. Clin. Oncol., 39, 625-631.
11. Elstner,A.et al. (2011) Identification of diagnostic serum protein profiles of glioblastoma patients. J. Neurooncol., 102, 71-80.
12. Ho,C.C.et al. (2009) Bone morphogenetic protein 2 signals via BMPR1A to regulate murine follicle-stimulating hormone beta subunit transcription. Biol. Reprod., 81, 133-141.
13. Lavery,K.et al. (2008) BMP-2/4 and BMP-6/7 differentially utilize cell surface receptors to induce osteoblastic differentiation of human bone marrow-derived mesenchymal stem cells. J. Biol. Chem., 283, 20948-20958.
14. Kirsch,T.et al. (2000) BMP-2 antagonists emerge from alterations in the low-affinity binding epitope for receptor BMPR-II. EMBO J., 19, 3314-3324.
15. Juric,D.et al. (2007) Integrated high-resolution genome-wide analysis of gene dosage and gene expression in human brain tumors. Methods Mol. Biol., 377, 187-202.
16. Gong,H.et al. (2005) The role of small RNAs in human diseases: potential troublemaker and therapeutic tools. Med. Res. Rev., 25, 361-381.
17. Calin,G.A.et al. (2006) MicroRNA-cancer connection: the beginning of a new tale. Cancer Res., 66, 7390-7394.
18. Laddha,S.V.et al. (2013) Genome-wide analysis reveals downregulation of miR-379/miR-656 cluster in human cancers. Biol. Direct, 8, 10.
19. Liu,T.et al. (2013) TNFAIP8 as a predictor of metastasis and a novel prognostic biomarker in patients with epithelial ovarian cancer. Br. J. Cancer, 109, 1685-1692.
20. Helland,O.,et al. (2012) Establishment of a bioluminescence orthotopic mouse model of ovarian carcinoma: analysis of tumor growth and response to therapy. Acta Obstet. Gyn. Scan, 91, 16-17.
21. López-Rovira,T.et al. (2002) Direct binding of Smad1 and Smad4 to two distinct motifs mediates bone morphogenetic protein-specific transcriptional activation of Id1 gene. J. Biol. Chem., 277, 3176-3185.
22. Nakada,M.et al. (2003) The role of matrix metalloproteinases in glioma invasion. Front. Biosci., 8, e261-e269.
23. Hagiwara,M.et al. (2007) Cross-talks between transcription and post-transcriptional events within a 'mRNA factory'. J. Biochem., 142, 11-15.
24. Chen,K.et al. (2007) The evolution of gene regulation by transcription factors and microRNAs. Nat. Rev. Genet., 8, 93-103.
25. Bartel,D.P. (2009) MicroRNAs: target recognition and regulatory functions. Cell, 136, 215-233.
26. Glazov,E.A.et al. (2008) Origin, evolution, and biological role of miRNA cluster in DLK-DIO3 genomic region in placental mammals. Mol. Biol. Evol., 25, 939-948.
27. Khan,S.et al. (2013) miR-379 regulates cyclin B1 expression and is decreased in breast cancer. PLoS One, 8, e68753.
28. Ma,R.et al. (2012) Downregulation of miR-544 in tissue, but not in serum, is a novel biomarker of malignant transformation in glioma. Oncol. Lett., 4, 1321-1324.
29. Rani,S.et al. (2013) Global analysis of serum microRNAs as potential biomarkers for lung adenocarcinoma. Cancer Biol. Ther., 14,.
30. Rosen,V. (2009) BMP2 signaling in bone development and repair. Cytokine Growth Factor Rev., 20, 475-480.
31. Food and Drug Administration. (2010) Food and Drug Administration Executive Summary for P050036 Medtronic's AMPLIGYTM rhBMP-2 Matrix Orthopaedic and Rehabilitation Devices Advisory Panel. 2010. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/MedicalDevices/MedicalDevicesAdvisoryCommittee/OrthopaedicandRehabilitationDevicesPanel/UCM220079.pdf (9 February 2014, date last accessed).
32. Kang,M.H.et al. (2010) BMP2 accelerates the motility and invasiveness of gastric cancer cells via activation of the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Exp. Cell Res., 316, 24-37.
33. Sun,D.et al. (2013) RAS/MEK-independent gene expression reveals BMP2-related malignant phenotypes in the Nf1-deficient MPNST. Mol. Cancer Res., 11, 616-627.
34. Liu,J.et al. (2012) BMP2 induces PANC-1 cell invasion by MMP-2 overexpression through ROS and ERK. Front. Biosci. (Landmark Ed)., 17, 2541-2549.
35. Jin,H.et al. (2012) BMP2 promotes migration and invasion of breast cancer cells via cytoskeletal reorganization and adhesion decrease: an AFM investigation. Appl. Microbiol. Biotechnol., 93, 1715-1723.
36. Kokorina,N.A.et al. (2012) rhBMP-2 has adverse effects on human oral carcinoma cell lines in vivo. Laryngoscope, 122, 95-102.
37. Langenfeld,E.M.et al. (2003) The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis, 24, 1445-1454.
38. Lai,T.H.et al. (2008) Osteoblasts-derived BMP-2 enhances the motility of prostate cancer cells via activation of integrins. Prostate, 68, 1341-1353.
39. Klose,A.et al. (2011) Imaging bone morphogenetic protein 7 induced cell cycle arrest in experimental gliomas. Neoplasia, 13, 276-285.
40. Feng,X.H.et al. (2005) Specificity and versatility in tgf-beta signaling through Smads. Annu. Rev. Cell Dev. Biol., 21, 659-693.
41. Bragdon,B.et al. (2011) Bone morphogenetic proteins: a critical review. Cell. Signal., 23, 609-620.
42. Nickel,J.et al. (2001) The crystal structure of the BMP-2:BMPR-IA complex and the generation of BMP-2 antagonists. J. Bone Joint Surg. Am., 83-A (suppl. 1), S7-14.
43. Liu,S.et al. (2012) Over-expression of BMPR-IB reduces the malignancy of glioblastoma cells by upregulation of p21 and p27Kip1. J. Exp. Clin. Cancer Res., 31, 52.
44. Massagué,J.et al. (2000) Transcriptional control by the TGF-beta/Smad signaling system. EMBO J., 19, 1745-1754.
45. Lu,L.et al. (2010) Synergistic effect of TGF-beta superfamily members on the induction of Foxp3+ Treg. Eur. J. Immunol., 40, 142-152.
46. Nohe,A.et al. (2002) The mode of bone morphogenetic protein (BMP) receptor oligomerization determines different BMP-2 signaling pathways. J. Biol. Chem., 277, 5330-5338.